Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.
暂无分享,去创建一个
M. Ladanyi | A. Drilon | C. Rudin | M. Kris | M. Rosenblum | W. Travis | M. Arcila | Gregory Riely | R. Somwar | N. Rekhtman | R. Benayed | M. Offin | Bob T. Li | A. Plodkowski | Helena A. Yu | J. Eng | Jason C. Chang | A. Lui | H. Yu
[1] E. Giovannetti,et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer , 2019, British Journal of Cancer.
[2] Y. Shu,et al. Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors , 2019, Cancer management and research.
[3] E. Santoni-Rugiu,et al. Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance , 2019, Cancers.
[4] Yong He,et al. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. , 2018, Lung cancer.
[5] M. Ladanyi,et al. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance , 2018, Clinical Cancer Research.
[6] Yunpeng Liu,et al. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients , 2018, Clinical Cancer Research.
[7] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[8] S. Ou,et al. Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature , 2017, Lung Cancer.
[9] Y. Chae,et al. P3.02-034 Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma , 2017 .
[10] S. Ou,et al. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients , 2017, Lung cancer.
[11] C. Azzoli,et al. MET amplification (amp) as a resistance mechanism to osimertinib. , 2017 .
[12] Hiroshi Sato,et al. In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET , 2017, Oncotarget.
[13] J. Shih,et al. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] Chia-Chi Lin,et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Ahn,et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.
[16] M. Ladanyi,et al. Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations , 2016, Clinical Cancer Research.
[17] Ash A. Alizadeh,et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.
[18] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[19] Aleksandra Markovets,et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.
[20] A. Iafrate,et al. Anchored multiplex PCR for targeted next-generation sequencing , 2014, Nature Medicine.
[21] Masao Iwata,et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. , 2013, Cancer letters.
[22] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[23] M. Kris,et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] B. Taylor,et al. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. , 2017, Cancer discovery.